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Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily
aﬀects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no signiﬁcant improvements in
prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain
focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma
expands, potential therapeutic targets are being identiﬁed. A comprehensive understanding of these mechanisms is essential if
we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the
pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational
studies performed to date in search of novel, safer, and more targeted drugs for disease management.
1.Introduction
Osteosarcoma is a relatively uncommon cancer although
it is the most common primary malignancy to arise from
bone. While incidence is low, osteosarcoma predominately
aﬀects adolescents and young adults, and if untreated it
is fatal. Despite modern treatment protocols that combine
chemotherapy, surgery, and sometimes radiotherapy, the 5-
year survival rate for patients diagnosed with osteosarcoma
remains at 60%–70% [1]. Current treatments for osteosar-
coma are associated with signiﬁcant morbidity, and a period
of rehabilitation may be required following surgery for
osteosarcoma. Hence, there is a real need to optimise current
treatment strategies and to develop novel approaches for
treating osteosarcoma.
Traditionally, our understanding of osteosarcoma has
been largely anatomical. Osteosarcoma arises most com-
monly in the metaphyseal region of long bones, within the
medullary cavity, and penetrates the cortex of the bone to
involve the surrounding soft tissues. A pseudocapsule forms
around the penetrating tumour [2]. Histologically, osteosar-
coma is characterised as a highly cellular tumour composed
of pleomorphic spindle-shaped cells capable of producing an
osteoid matrix. Current standards for staging and surgical
resection rely on this anatomical knowledge [3]. However,
recent developments in molecular biology have provided
insight into the molecular pathogenesis of osteosarcoma.
Through the identiﬁcation of tumour pathways and speciﬁc
mediators of osteosarcoma progression, novel approaches
for targeting osteosarcoma are being developed. This paper
will review our current understanding of the molecular
pathogenesis of osteosarcoma.
2. Pathogenesis
2.1. Bone Growth and Tumorigenesis. Osteosarcoma has a
predilection for developing in rapidly growing bone. A
number of studies have established a correlation between
the rapid bone growth experienced during puberty and
osteosarcoma development [4, 5]. Fifty-six percent of all
osteosarcomas present around the knee [2]. The epiphyseal
growth plates of the distal femur and proximal tibia are
responsible for a great deal of the increase in height
that occurs during puberty. Additionally, the peak age of2 Sarcoma
osteosarcoma development is slightly earlier for females, an
observation that may be explained by the relatively earlier
growth spurt experienced by girls [6]. There is a male:female
ratio of 1.5:1 for osteosarcoma, and patients aﬀected by the
disease are taller compared to the normal population of the
same age group [7]. Patients aﬀected by Paget’s disease, a
disorder characterised by both excessive bone formation and
breakdown,alsohaveahigherincidenceofosteosarcoma[2].
2.2. Environmental Factors. Physical, chemical, and biologi-
cal agents have been suggested as carcinogens for osteosar-
coma. Among these, the role of ultraviolet and ionising
radiation is the best established. The initial pathogenic link
between radiation exposure and osteosarcoma was noted in
female radium dial workers who applied radium to watch
faces to make them luminescent [8]. However, radiation
exposure is implicated in only 2% of cases of osteosarcoma
[9] and is not thought to play a major role in paediatric
disease. An interval of 10–20 years between exposure and
osteosarcoma formation has been observed [10]. When
radiotherapy is used in children as a treatment agent for a
solid tumour, 5.4% develop a secondary neoplasm, and 25%
of these are sarcomas [11].
The chemical agents linked to osteosarcoma forma-
tion include methylcholanthrene and chromium salts [12],
beryllium oxide [13], zinc beryllium silicate [14], asbestos,
and aniline dyes [15]. Previously, a viral origin had been
suggested for osteosarcoma. This stemmed from the detec-
tion of simian virus 40 (SV40) in osteosarcoma cells.
However, the presence of SV40 in these cells was later
concluded to be the result of presence of SV40 viral units as
contamination in the polio-virus vaccine that these patients
h a dr e c e i v e d[ 16, 17]. Studies evaluating the role of SV40
in the pathogenesis of mesothelioma have suggested that
detection of SV40 in human cancers may in fact be due
to laboratory contamination by plasmids containing SV40
sequences [18, 19].
2.3. Chromosomal Abnormalities. A number of chromoso-
mal and genetic syndromes have been linked to osteosa-
rcoma. Osteosarcoma has been reported in patients with
Bloom syndrome, Rothmund-Thompson syndrome, Werner
syndrome, Li-Fraumeni syndrome, and hereditary retino-
blastoma [15]. Bloom, Rothmund-Thompson, and Werner
[20] syndromes are characterised by genetic defects in the
RecQ helicase family. DNA-helicases are responsible for
separation of double-stranded DNA prior to replication [21,
22]. Mutations in these genes confer a higher risk of multiple
malignancies.
A recent study of pretherapeutic biopsy specimens has
identiﬁed ampliﬁcations of chromosomes 6p21, 8q24, and
12q14, as well as loss of heterozygosity of 10q21.1, as
being among the most common genomic alterations in
osteosarcoma. Furthermore, it was concluded that patients
carrying these alleleshadapoorer prognosis [23]. Numerical
chromosomal abnormalities associated with osteosarcoma
include loss of chromosomes 9, 10, 13, and 17 as well as gain
of chromosome 1 [24].
2.4. Tumour Suppressor Gene Dysfunction. When human
cells are exposed to environmental insults, such as those
discussed above, somatic DNA may be damaged. Such DNA
damage may not necessarily give rise to a malignant cell line,
as there are a number of tumour-suppressor mechanisms in
place. These mechanisms may either repair the DNA damage
or induce apoptosis of these cells. The p53 and retinoblas-
toma (Rb) genes are well-known tumour-suppressor genes.
However, tumour suppressor genes may themselves become
mutated, resulting in the loss of their protective function.
As a result, additional somatic mutations may accumulate,
giving rise to a cell line that replicates without restraint.
Mutations in both the p53 and Rb genes have been proven
to be involved in osteosarcoma pathogenesis [6].
Thep53geneismutatedin50%ofallcancersand22%of
osteosarcomas[24].DNAdamageresultsinphosphorylation
of p53, which is constitutively inhibited by Mdm2. Phospho-
rylation allows p53 dissociation from Mdm2. p53 exerts its
tumour-suppressor eﬀects via the activation of proapoptotic
Bax and p21. The latter binds and inactivates G1/S-Cdk and
S-Cdk complexes, causing arrest of the cell cycle in G1 [25].
Recently, p53 mutations have been shown to result in
impaired DNA repair mechanisms and disrupted antian-
giogenesis activity [26]. For osteosarcoma, the prototypi-
cal condition of p53 mutation is Li-Fraumeni syndrome.
This syndrome is characterised by an autosomal dominant
mutation of p53 leading to the development of multiple
cancersincludingosteosarcoma[27].Li-Fraumenisyndrome
and germ-line mutations of p53 in osteosarcomas are rare,
however [28], and in many osteosarcoma cell lines, a
mutation in the ﬁrst intron of the p53 gene occurs [29]
though other point mutations have also been reported [30].
While p53 has been implicated in the oncogenesis
of osteosarcoma, it is unclear whether p53 mutation or
loss may aﬀect tumour behaviour. Using the p53-null
SaOS-2 osteosarcoma cell line, Ganjavi et al. [31] showed
that adenoviral-mediated gene transfer of wild-type p53
resulted in reduced cell viability and increased sensitivity to
chemotherapeutic agents. A recent study published by Hu et
al. [32] showed that p53 expression was higher in low Rosen
grade osteosarcomas (Rosen grade 1: <50% necrosis; grade
2:50%–90%necrosis;grade3:>90%necrosis;grade4:100%
necrosis; grade 1 + 2 = low-grade; grade 3 + 4 = high grade).
p53 expression correlated with reduced metastatic disease
and improved survival for these patients. p53 mutation has
also been shown to be more common in high-grade conven-
tional osteosarcomas versus low grade central osteosarcomas
[33]. However, other studies diﬀer such as that of Lonardo
et al. [34], which found no relationship between p53 and
histological grade. Univariate analysis performed by Park et
al. [35] showed no correlation between survival and the p53
protein, while coexpression of p53 and P-glycoprotein was
associated with a poorer prognosis.
In addition to p53, the Rb tumour suppressor has
also been implicated in the tumorigenesis of osteosarcoma.
The Rb gene is critical to cell-cycle control, and inherited
mutation of the Rb gene causes retinoblastoma syndrome, a
conditionthatpredisposesapatienttomultiplemalignancies
including osteosarcoma. The Rb protein regulates the cellSarcoma 3
cycle by binding the transcription factor E2F. E2F is held
inactive by Rb until the CDK4/cyclin D complex phospho-
rylates Rb. Mutations of Rb allow for the continuous cycling
of cells [25].
Both germ-line and somatic mutations of Rb confer an
increased risk of osteosarcoma. Loss of the Rb gene may even
explain the familial risk of osteosarcoma [36]. However, it
hasyettobedeterminedwhetherRbgenelossorsuppression
g i v e sr i s et om o r ea g g r e s s i v et u m o u r sw i t hp o o r e rp r o g n o s i s .
Loss of heterozygosity for Rb has been reported to confer
bothanimprovedandpoorerprognosisforpatients[37–40].
In terms of response to chemotherapeutic treatment, Iida et
al. [41] showed that the SaOS-2 osteosarcoma cell line, lack-
ing active Rb, was less sensitive to the growth-suppressing
eﬀect of methotrexate compared to cell lines with wild-type
Rb gene. Further studies are warranted to investigate the role
of Rb on chemosensitivity of osteosarcoma cells.
2.5. Transcription Factors. Transcription is the process of
forming single-stranded messenger RNA (mRNA) sequences
from double-stranded DNA. Transcription factors facilitate
binding of promoter sequences for speciﬁc genes to initiate
the process. While transcription is usually tightly regulated,
deregulation may occur in osteosarcoma, as with other
cancers. Excess production of transcription factors, or the
production of a new overactive transcription factor, may
result from gene rearrangement.
The activator protein 1 complex (AP-1) is a regulator of
transcription that controls cell proliferation, diﬀerentiation,
and bone metabolism. AP-1 is comprised of Fos and Jun
proteins, products of the c-fos and c-jun proto-oncogenes,
respectively. Fos and Jun are found to be signiﬁcantly upreg-
ulated in high-grade osteosarcomas compared with benign
osteoblastic lesions and low-grade osteosarcomas [42, 43]
and are associated with the propensity to develop metastases
[44]. Fos and Jun double-transgenic mice are found to
develop osteosarcomas with a higher frequency than c-
Fos only transgenic mice [45]. Most recently, Leaner et al.
[46] showed that inhibition of AP-1-mediated transcription
caused reduced migration, invasion, and metastasis in a
murine model of osteosarcoma. Another approach has been
totargettheJuncomponentofAP-1.TheDNAenzymeDz13
cleaves human c-Jun mRNA and is capable of inhibiting
osteosarcoma growth and progression in a clinically relevant
murine model when delivered by nanoparticle vector [47].
Myc is a transcription factor that acts in the nucleus to
stimulate cell growth and division. Myc ampliﬁcation has
been implicated in osteosarcoma pathogenesis and resistance
to chemotherapeutics. Overexpression of Myc in bone
marrow stromal cells leads to osteosarcoma development
and loss of adipogenesis [48]. Myc is ampliﬁed in U2OS
osteosarcoma cell-line variants with the highest resistance
to doxorubicin, and gain of Myc was found in SaOS-2
methotrexate-resistant variants [49]. Additionally, Myc has
been examined as a therapeutic target for osteosarcoma.
Downregulation of Myc enhanced the therapeutic activity of
methotrexate against osteosarcoma cells [50]. Adenovirus-
mediated transfection with the antisense Myc fragment led
to cell-cycle arrest and enhanced apoptosis in the MG-63
osteosarcoma cell line [51]. Using a conditional transgenic
mouse model, Arvanitis et al. [52] showed that Myc inac-
tivation caused proliferative arrest and promoted diﬀeren-
tiation in osteosarcoma. Additionally, using positron emis-
sion tomography (PET), these tumours exhibited reduced
metabolic activity as demonstrated by reduced uptake of
[18F]-ﬂuorodeoxyglucose ([18F]-FDG).
2.6. Growth Factors. Osteosarcoma cells produce a range of
growth factors that exert autocrine and paracrine eﬀects.
Dysregulatedexpressionofgrowthfactorssuchastransform-
ing growth factor (TGF), insulin-like growth factor (IGF),
and connective tissue growth factor (CTGF) leads to the
accelerated proliferation of cells. Growth factor receptors
may be overexpressed and constitutively activated. Signal
transduction associated with these receptors may also be
overactivated.
Transforming growth factor beta (TGF-β) proteins are
a large family of dimeric proteins secreted by cells. Like
many other growth factors, they inﬂuence a wide variety
o fc e l lp r o c e s ss u c ha sd i ﬀerentiation, proliferation, apop-
tosis, and matrix production. Bone morphogenic proteins
(BMPs) make up a large component of the TGF-β family.
High-grade osteosarcomas are found to express TGF-β1i n
signiﬁcantly higher amounts than low-grade osteosarcomas
[53]. Navid et al. [54] examined the autocrine role of TGF-
β on two osteosarcoma cell lines, demonstrating a 30%–
50% reduction in growth when osteosarcoma cells were
cultured in the presence of TGF-β-blocking antibody. Smad
activation was implicated downstream of TGF-β with an
inability to phosphorylate the Rb protein. Most recently, Hu
et al. [55, 56] have shown an association between increased
susceptibility and metastasis of osteosarcoma with TGFR1
variants, TGFBR1∗6A, and Int7G24A.
IGF (insulin-like growth factor)-I and IGF-II are growth
factors that are often overexpressed by osteosarcomas.
These ligands bind corresponding receptors such as IGF-1R,
leading to activation of the PI3K and MAPK transduction
pathways. This, then, supports cell proliferation and inhi-
bition of apoptosis [57]. The growth-stimulating eﬀect of
IGFhasbeentargetedforosteosarcoma.Lentivirus-mediated
shRNA targeting IGF-R1 enhanced the chemosensitivity of
osteosarcoma cells to docetaxel and cisplatin [58]. The use of
monoclonal antibodies targeting IGF-R1 was also eﬀective in
enhancing antitumour response [59, 60].
Connective tissue growth factor (CTGF) is related to a
number of proteins in the CCN family (CTGF/Cyr61/
Cef10/NOVH). This protein family appears to act via inte-
grin signalling pathways [61] and, like TGF-β,h a sad i v e r s e
range of functions including adhesion, migration, prolifer-
ation, survival, angiogenesis, and diﬀerentiation. Nishida et
al. [62] showed that CTGF is a potent stimulator for the
proliferation of SaOS-2 cells, leading to increased expres-
sion of type I collagen, alkaline phosphatase, osteopontin,
and osteocalcin, markers for bone cell diﬀerentiation and
maturation. A related protein, CCN3, was found to be
overexpressed in osteosarcoma and associated with a worse
prognosis [63].4 Sarcoma
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Figure 1: Pathways disrupting anoikis.
Parathyroid hormone (PTH), parathyroid hormone-
related peptide (PTHrP), and the receptor (PTHR1) have
been implicated in the progression and metastasis of
osteosarcoma. PTHrP was discovered as the humoral factor
associated with tumour metastasis and hypercalcaemia [64].
The role of PTHrP and PTHR1 in osteoclast signalling will
be discussed later. In terms of direct eﬀects on osteosarcoma
cells, when HOS osteosarcoma cells were overexpressed
with PTHR1, increased proliferation, motility, and invasion
through Matrigel were observed [65]. Gagiannis et al.
[66] recently showed that PTHrP confers chemoresistance
in osteosarcoma by blocking signalling via p53, death-
receptor and mitochondrial pathways of apoptosis. PTHrP
downregulated expression of proapoptotic Bax and PUMA
and upregulated antiapoptotic Bcl-2 and Bcl-xl. Berdiaki
et al. [67], using MG-63 and SaOS-2 osteosarcoma cell
lines, showed that PTH peptides enhanced osteosarcoma cell
migration through the regulation of hyaluron metabolism.
However, a previous study showed that overexpression of
PTHrP in a murine osteoblastic osteosarcoma cell line re-
duced cell proliferation by 80% [68]. Further studies are
required to determine the prognostic signiﬁcance of PTH/
PTHrP/PTHR1 signalling in osteosarcoma.
2.7. Osteosarcoma Cell Proliferation, Apoptosis, and Anchora-
ge-Independent Growth. Cancer cells are relatively resistant
toapoptosis, andthis ability toavoid elimination contributes
to the ability of osteosarcoma cells to proliferate without
restriction. Apoptosis consists of initiation and execution
phases. During initiation, enzymes responsible for the
cleavage of vital cellular proteins, known as caspases, are
activated. Execution refers to the actual process of hydrolysis
performed by activated caspases. Both extrinsic and intrinsic
pathways regulate the initiation phase. The extrinsic pathway
is a death receptor-initiated pathway, while the intrinsic
pathway relies on increased mitochondrial permeability.
Both proapoptotic and antiapoptotic factors interact with
these pathways, and these have been discussed in a previous
review [69].
Anoikis is a form of apoptosis that is induced when
cells are no longer attached to a basement membrane or
matrix. This is of particular interest in osteosarcoma given
the propensity of osteosarcoma cells to detach from matrix
components and to metastasise. Osteosarcoma cells are
resistant to anoikis and proliferate despite deranged cell-cell
and cell-matrix attachments. This resistance to anoikis is
termed anchorage-independent growth (AIG).
The pathways causing anoikis disruption and leading to
anchorage-independent growth are complex. They involve
interactions between integrin signalling, Rho GTPases,
PI3 kinase, and PKB/Akt activation, along with many key
componentsoftheintrinsicandextrinsicapoptosispathways
(Figure 1). For example, when normal cells adhere to sur-
rounding matrix via integrin-ﬁbronectin binding, the Bcl-2
inhibitor Bit1 is suppressed allowing Bcl-2 to prevent apop-
tosisviatheintrinsicpathway[70].Anotherpathwayinvolves
the exchange of integrin subunits resulting in the production
of abnormal integrins, such as αvβ6, which can upregulate
PI3 kinase function [71]. PI3 kinase can then activate
PKB/Akt which inhibits the proapoptotic factor Bad, leadingSarcoma 5
to cancer cell survival [72]. Rho GTPases such as Rac1 and
Cdc42 can also upregulate PI3 kinase with similar conse-
quences [73]. Increased epidermal growth factor-receptor
(EGF/EGFR) binding with subsequent extracellular signal-
regulated kinase (Erk)/microtubule-associated protein kina-
se (MAPK) signalling leading to inhibition of Bim has also
beendescribed[74].Thissuppressescelldeath,asBimwould
normally act to increase mitochondrial outer membrane
permeability allowing release of cytochrome c and then the
activation of executioner caspases.
2.8. Tumour Angiogenesis. Tumour angiogenesis is essential
for sustained osteosarcoma growth and metastasis. Without
a supporting vasculature, osteosarcoma cells would be
unable to obtain the nutrients and oxygen necessary for
proliferation. Metastasis to the lungs and bone, the most
common sites for osteosarcoma spread, also relies on the
formation and maintenance of blood vessels. Radiation
therapies, while compromising tumour cells, also destroy the
vascular component of tumours and block the supply of
nutrients. So, radio- and chemotherapies act by these dual
actions. This aspect is discussed below.
A balance between pro-angiogenic and antiangiogenic
factors regulates angiogenesis, and this balance is tipped
towards the favour of neovascularisation by tissue hypoxia,
acidosis, oncogene activation, and loss of tumour suppressor
gene function. A hypoxic and acidotic microenvironment
exists around proliferating osteosarcoma cells, and these
conditions stimulate deubiquitination of von Hippel Lin-
dau protein. Von Hippel Lindau protein releases hypoxia-
inducible factor-1α (HIF-1α), allows HIF-1α to bind to the
promoter region of the vascular endothelial growth factor
(VEGF) gene [75], and upregulats it. TGF-α,a n dﬁ b r o b l a s t
growth factor (FGF) may also upregulate VEGF [76].
VEGF is the best-characterised pro-angiogenic factor,
and it stimulates the processes of endothelial cell prolifera-
tion, migration, and blood vessel maturation. A number of
diﬀerent VEGF molecules exist (VEGF-A through to VEGF-
E), and these proteins bind to VEGF receptors (VEGFR1-
3) [77]. VEGF-A has the broadest angiogenic eﬀect. Upon
VEGF-A binding to VEGFR2, a number of divergent sig-
nalling pathways are initiated [77]. Nitric oxide (NO) is
released by endothelial cells, leading to vasodilation and
increased vascular permeability [78]. Endothelial cell pro-
liferation and cycling are stimulated via phospholipase Cγ
(PLCγ), protein kinase C (PKC), and the c-Raf-MEK-MAPK
cascades [77]. Rearrangement of the actin cytoskeleton,
necessary for endothelial cell migration occurs via phospho-
rylation of T cell-speciﬁc adapter (TSAd) and interaction
with Src, another protein kinase [79]. The net result of all
thesechangesistheformationofanimmature,irregular,and
leaky vascular network.
Theimmatureandineﬃcientnatureofthevesselssopro-
duced facilitates feedback loops for further vessel formation.
Upregulation of HIF-1α and VEGF [80] again occurs as the
leaky vasculature is unable to meet the metabolic demands
of the proliferating osteosarcoma cells. Additionally, VEGF
upregulates matrix metalloproteinase (MMP) and plasmin
activity [81]. These proteases break down extracellular
matrix, which releases any VEGF combined with heparin
proteoglycan in the matrix. VEGF also induces antiapoptotic
factors Bcl-2, and survivin, ensuring ongoing endothelial
proliferation [82]. In addition to VEGF, the proliferating
tumour cells release a number of other pro-angiogenic
factors. These include FGF, platelet-derived growth factor
(PDGF), angiopoietin1 (Ang1), and ephrin-B2 [83, 84].
While it is known that osteosarcoma is a relatively
vascular tumour, the prognostic signiﬁcance of this is yet
to be determined. There have been studies suggesting both
a correlation [85, 86] and lack of association [87]b e t w e e n
VEGF expression and osteosarcoma microvascular density
and metastases at diagnosis. This may relate to a greater
tumour dependence on functionally mature vessels. One
study that demonstrated a survival advantage associated
with increased osteosarcoma microvascular density [88]
attributed this advantage to improved tissue penetration by
chemotherapeutic agents.
Aspreviouslymentioned,angiogenesisisregulatedbythe
balance between pro-angiogenic and antiangiogenic factors.
Antiangiogenic proteins such as thrombospondin 1, TGF-β
[89], troponin I, pigment epithelial-derived factor (PEDF)
[90],andreversion-inducing cysteine rich protein with Kazal
motifs (RECK) [91] are downregulated in osteosarcoma.
These antiangiogenic molecules are particularly important
for embryogenesis and physiological processes such as
wound healing and menstruation; however, they also play a
protectivemechanismagainstosteosarcomaprogression.For
example, troponin I and PEDF are expressed predominately
within the avascular zones of the cartilaginous growth
plate [92, 93] and are likely to contribute to growth
plate resistance to osteosarcoma invasion from a typical
metaphyseal location. In addition to inhibiting angiogenesis,
PEDFexertsdirecteﬀectsonosteosarcomacells.Eketal.[94,
95] have demonstrated apoptosis induction in osteosarcoma
cell lines treated with PEDF. Also, in a murine model of
orthotopic osteosarcoma, tumour volume was reduced by
PEDF, which was associated with reduced microvascular
density.Therewasdecreasedtumourmetastasesandreduced
size of metastatic tumours in lung.
2.9. Cell Adhesion and Migration. Osteosarcoma is a highly
metastatic tumour, and pulmonary metatases are the most
common cause of death. The metastatic sequence involves
the detachment of osteosarcoma cells from the primary
tumour, adhesion to the extracellularmatrix, local migration
and invasion through stromal tissue, intravasation, and
extravasation.Theabilityofosteosarcomacellstometastasise
by such a pathway relies on complex cell-cell and cell-matrix
interactions.
The extracellular matrix is composed of various protein
ﬁbrils and growth factors. The proteins include ﬁbronectin,
collagens, proteoglycans, and laminins. Osteosarcoma cells
may also produce matrix proteins. The extracellular matrix
provides a developing tumour with a supporting scaﬀold
and facilitates blood vessel formation. Osteosarcoma cells
adhere to matrix components via cell-surface receptors.
T h e s er e c e p t o r sa r em o r et h a nj u s tap h y s i c a lp o i n to f
attachment; they also provide a link between matrix proteins6 Sarcoma
and the cytoskeleton. The principle receptor proteins are
the integrins, which bind to the matrix protein ﬁbronectin.
There are 24 diﬀerent integrin heterodimer molecules con-
sisting of diﬀerent α and β subunits [96].
Theintegrinsalsoplayaroleincellsignaling,particularly
in pathways critical to cell migration. Integrin-binding
proteinssuchastalinbecomeassociatedwiththecytoplasmic
domain and act, via adaptor proteins such as vinculin,
paxillin, and α-actin, for the upregulation of protein kinases
[97] .T h ek e ye n z y m e si n v o l v e dh e r ea r ef o c a la d h e s i o n
kinase (FAK), protein kinase C (PKC), PI3 kinase, Src, and
the RhoA GTPases.
The relative activities of these enzymes underlie con-
formational changes in cell architecture. For example, there
is a shifting balance between two of the RhoA GTPases:
Rac1 and RhoA. High Rac1 expression suppresses RhoA and
induces the formation of membrane ruﬄes. These mem-
brane changes facilitate cell spreading and migration [98].
Conversely, high RhoA with low Rac1 leads to membrane
retraction. These two processes are coordinated such that in
cell migration, the leading edge of the cell is demonstrating
actin polymerisation and lamellipoedia, while the trailing
edge is undergoing actin disassembly. Inhibition of RhoA
pathways has been shown to reduce osteosarcoma cell
migration and invasion [99].
In general, cells migrate towards ligand-dense matrix
and towards more rigid matrix [100], indicating a constant
intracellular response to extracellular adhesion and tension.
Tumour stroma is more rigid than normal connective tissue
matrix, and this generates integrin clustering, activation
of intracellular signalling pathways, decreases cell-to-cell
contacts, and stimulates tumour growth [101].
The ezrin protein also has a role in cell-cell interactions,
signal transduction, linkage between actin ﬁlaments, and cell
membrane receptors such as CD44, which binds hyaluronan
in the extracellular matrix. When ezrin is overexpressed, it
is associated with an increase in metastasis [102]. Increased
ezrin expression in paediatric osteosarcoma patients is asso-
ciated with reduced disease-free intervals, and downregu-
lation of ezrin expression in a mouse model of human
osteosarcoma has been shown to reduce pulmonary metas-
tasis [103].
2.10. Tumor Invasion. Invasion of the surrounding tissues by
osteosarcoma also involves degradation of the extracellular
matrix. Matrix metalloproteinases (MMPs) are principally
involved in the breakdown of the extracellular matrix, alt-
hough roles in tumour angiogenesis have also been estab-
lished.
MMPs are a family of zinc-dependent endopeptidases
that are involved in a range of physiological processes
includinginﬂammation,woundhealing,embryogenesis,and
fracture healing. In normal tissues, MMPs are regulated
by natural inhibitors such as tissue inhibitors of MMPs
(TIMPs), RECK, and α2m a c r o g l o b u l i n[ 104]. In the setting
of osteosarcoma, MMPs break down extracellular collagens,
facilitating both tumour and endothelial cell invasion.
MMPs may be designated as gelatinases, collagenasesm, or
stromeolysins. Gelatinases break down denatured collagens
and type IV collagen. Collagenases break down type I, type
II, and type III collagen, and stromeolysins break down
proteoglycan (found in articular cartilage), type III, type IV
(in basement membranes), and type V collagen, as well as
casein and ﬁbronectin [105].
In addition to clearing a pathway for invading osteosar-
coma cells, the role of MMPs in angiogenesis has already
been mentioned. Remodelling of vessel walls by MMPs gives
rise to a thin and leaky vascular network that allows passage
of tumour cells into the bloodstream [106]. Furthermore,
MMP-9 releases VEGF stored within the extracellular matrix
[107], and VEGF is able to upregulate MMP-2 [108]. The
speciﬁcimportance ofthegelatinasesMMP-2andMMP-9to
tumour progression has been delineated in an in vivo study,
where combined MMP-2/MMP-9 deﬁciency in mice signiﬁ-
cantly impaired tumour angiogenesis and invasion [109].
The urokinase plasminogen activator (uPA) system is the
otherkeyregulatorofosteosarcomainvasion,whichinteracts
with MMPs. The ligand uPA binds to its receptor uPAR to
become active. Once activated, uPA cleaves plasminogen to
plasmin. Plasmin breaks down the extracellular matrix but
also activates pro-MMPs. A cascade of activation is hence
established [110, 111]. The role of the uPA-uPAR system is
well established in osteosarcoma pathogenesis. An inverse
relationship between uPA levels and survival time has been
demonstrated [112] .D o w n r e g u l a t i o no fu P A Ri na nin vivo
osteosarcoma model resulted in reduced primary tumour
growth and fewer metastases [113].
2.11. Osteoclast Function. Osteosarcoma invasion of bone
reliesoninteractionsbetweenthebonematrix,osteosarcoma
cells, osteoblasts, and osteoclasts (Figure 2). Osteoclasts
are the principle bone-resorbing cells, and the substantial
osteolysis exhibited by some osteosarcomas is the direct
result of increased osteoclastic activity. During the initial
stages of osteosarcoma invasion, growth factors such as
TGF-β are released from the degraded bone matrix and
act on osteosarcoma cells, stimulating the release of PTHrP,
interleukin-6 (IL-6) and interleukin-11 (IL-11) [114, 115].
These cytokines then stimulate osteoclasts, facilitating fur-
ther invasion and release of proresorptive cytokines.
Osteoblasts are, in fact, mediators in this process of bone
resorption. Osteosarcoma cells release endothelin-1 (ET-1),
VEGF, and PDGF in response to the hypoxic and acidotic
conditions. These factors have predominantly osteoblast-
stimulatory functions [116, 117]. PTHrP and IL-11 also act
on osteoblasts, stimulating increased expression of receptor
activator of nuclear factor κB ligand (RANKL). RANKL
is a key mediator of osteoclast diﬀerentiation and activity,
and osteosarcoma cells have been noted to produce RANKL
independently [118].
RANKL activates osteoclasts through binding to RANK
on the osteoclast surface. RANK expression is under control
of cytokines IL-1, IL-6, IL-8, tumour necrosis factor-α
(TNF-α), PTHrP, and TGF-α [119]. Receptor-ligand binding
initiates a cascade of events through binding of TRAF-6,
leading to activation of both NFκB and MAPK pathways,
with a resulting increase in nuclear factor of activated T-
cells (NFATc1) activity. RANK/RANKL also activates theSarcoma 7
RANKL
RANK
Cathepsin K
Cancer cells
CXCR4
SDF-1
Osteoblastic stimulus
VEGF PDGF, ET-1
PTHrP,
IL-6, 11
TGFβ, IGFs
OPG
Bone matrix
Acid pH, hypoxia, Ca2+, TGF, IGF
Figure 2: Vicious cycle of osteolysis by osteoclasts.
c-Fos component of AP-1, resulting in additional NFATc1
upregulation. NFATc1 is thus a common end-point for
eﬀecting transcription of genes involved in osteoclast activity
and maturation [120].
Activated osteoclasts release proteases to resorb the
nonmineralised components of bone. Cathepsin K (Cat K)
is a cysteine protease selectively produced by osteoclasts for
breakdownofcollagenI,osteopontin,andosteonectin[121].
Cat K is also produced by some cancer cells to aid invasion
[122]. This protease is essential for osteoclast function in
normal bone remodelling and also in pathological states of
osteolysis. For patients with high-grade metastatic osteosar-
coma, low Cat K levels at the time of diagnosis confers a
better prognosis [123].
c-Src is a nonreceptor tyrosine kinase present within
osteoclasts [124] and is involved in pathways regulating cell
growth, survival, and migration [125]. Osteoclast survival
occurs through c-Src mediating phosphatidylinositol 3-
kinase and TRAF-6 interaction, with resulting Akt/mTOR
(mammalian target of rapamycin) pathway activation and
then inhibition of caspase-3 [126]. Podosome assembly,
vesicle transport, secretion of proteases, and organisation
of microtubules are all regulated by c-Src pathway activity
[127]. For osteosarcoma, inhibition of c-Src induces apopto-
sis and inhibits invasion in vitro. Primary tumour volume in
a murine model of osteosarcoma was also reduced by c-Src
inhibition [128].
Osteoclast pathways of diﬀerentiation, maturation, and
activation have potential as therapeutic targets. Inhibition
of bone resorption at the tumour-bone interface may lead
to reduced local invasion by osteosarcoma. The central
role that RANKL plays in osteoclast function makes it a
particularly attractive target. Osteoprotegerin (OPG) is a
soluble decoy receptor for RANKL and strongly suppresses
osteoclast diﬀerentiation both in vitro and in vivo [129].
OPG gene therapy has been applied to a murine model of
osteosarcoma and successfully suppressed osteolytic activity.
There were a reduced number of osteoclasts associated with
tumours, leading to reduced local osteosarcoma progression
and improved survival [130].
3. SummaryandFutureDirections
Osteosarcoma is a relatively uncommon malignancy, with
an overall incidence of 5 cases per million persons per year.
However, among childhood malignancies, osteosarcoma is
theeighthmostcommon.Onlyleukaemias,lymphomas,and
neurological malignancies are more common. Osteosarcoma
accounts for 8.9% of cancer-related deaths in children and
carries an overall 5-year survival rate of 60%–70% [131].
However, being a disease that aﬀects patients in the prime
of their lives, incidence and survival rates do not accurately
reﬂect the true burden of this disease. The burden to patients
a n dt h ec o m m u n i t yi sp a r t i c u l a r l yh i g ha so u rc u r r e n t
treatments combine chemotherapy, often disabling surgery,
and prolonged periods of rehabilitation. The disability-
adjusted life year (DALY) was put forward by the World
Health Organisation (WHO) as a measure of overall burden
of disease. It is the number of years lost due to disability,
poor health, or premature death. For sarcomas, an average
of 17 life years per patient is lost, compared to 6.5 for bowel,
lung, and breast cancers. For this reason, the treatment of
osteosarcoma is a major public health issue.
Ottaviani and Jaﬀe[ 131] recently published a review
of the epidemiology of osteosarcoma. Death rates for
osteosarcoma are declining by a small 1.3% per year. Indeed,
there has been no signiﬁcant improvement in prognosis for
patients with osteosarcoma since the advent of multiagent
chemotherapy. Prior to chemotherapy, the overall survival
rate for osteosarcoma was a dismal 20% [132]. However,8 Sarcoma
the challenges we now face are paradoxically the result of
our application of modern chemotherapeutics. Resistance to
chemotherapy and the recurrence of disease, commonly in
the form of pulmonary metastases despite successful surgical
resection, are the two greatest challenges we face in regards
to the development of therapies for osteosarcoma.
Our understanding of the molecular basis of osteosar-
coma has advanced considerably over recent decades. The
processes involved in osteosarcoma oncogenesis have been
outlined above, and it is our hope that a molecular
understanding of the disease will lead to targeted treatment
of osteosarcoma. As is evident from the discussion above,
there are potentially multiple targets, and we must identify
and develop those with the most promise. Therapeutic
approaches may not target osteosarcoma cells themselves
but may seek to intervene in the complex biology between
osteosarcomas cells, osteocytes, osteoblasts, osteoclasts, and
even endothelial cells. Indeed, some of the more promising
therapeutic agents developed exploit multiple tumorigenic
pathways. For example, the potent antiangiogenic pigment
epithelium derived factor (PEDF) inhibits the supporting
vasculature of the developing tumour whilst also inhibiting
proliferation, invasion, and metastasis of osteosarcoma cells
[94, 133–135]. Similarly, reversion-inducing cysteine rich
protein with Kazal motifs (RECK) has been shown to reduce
microvascular density, tumour invasion, and metastasis
independently [136].
In this paper we have sought to outline the molecu-
lar pathogenesis of osteosarcoma with some reference to
potential therapeutic targets currently under investigation.
The genetic basis of osteosarcoma has been presented and
discussed,alongwiththeroleofkeytranscriptionfactorsand
growth factors. The processes of osteosarcoma cell prolifera-
tion, apoptosis, adhesion, invasion, and metastasis represent
potential biological targets for treating osteosarcoma. Osteo-
clast and endothelial cells may also be targeted. However,
the study of pathogenic mechanisms is in itself not enough.
Translational studies are critical if an eﬀective treatment
for osteosarcoma is to arise from this understanding of
osteosarcoma biology. The past decade has revealed a great
deal about osteosarcoma pathogenesis, and only with further
translational studies will, we see which of the many potential
targets and combination of therapies prove to be the most
eﬀective in treatment of this debilitating tumour.
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